CTMX: Lead ADC demonstrates promising efficacy in late-line CRC, with broad pipeline and strong financial runway
Masked biologics technology enables targeting of challenging cancer antigens, with lead ADC showing strong efficacy and improved tolerability in late-line CRC. Dose optimization and combination studies are advancing, with expansion into other GI cancers and a masked cytokine program in melanoma. Ca…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.